INTerpath-001 met recurrence-free and distant metastasis-free survival endpoints in 1,137 patients, giving individualized mRNA cancer therapy its first positive Phase 3 readout.
Ingenia Therapeutics gains dual Prix Galien nominations as its KOSDAQ debut puts MK-8748, IGT-303 and the broader TIE2 pipeline under scrutiny.
Merck’s alimatravir access plan covers 129 countries, but Phase 3 efficacy, pricing and regulatory execution will decide its HIV PrEP impact.
CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic TNBC, moving Gilead closer to an expanded EU label.
Scancell will acquire Neuphoria Therapeutics and pursue up to $89 million to fund the Phase 3 iSCIB1+ melanoma trial through 2028.
Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.
Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.
CEL-SCI launches a 212-patient Multikine Phase 3 study, but subgroup validation, funding and regulatory execution remain decisive.
See how Merck’s IDVYNSO ADAP agreement could widen HIV treatment access while pricing, formularies and clinical limits shape uptake.
The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.